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Objective: To assess SV in our RRT population in the period 1976–2012 as well as the inﬂuence
of  technique transference (TT).
Materials and methods: The study included a retrospective cohort of 993 patients. Data were
classiﬁed as transplant (Tx), change in technique, exitus or lost to follow-up. SV for TT was
determined in patients with over 12 weeks of permanence.
Results: The mortality risk adjusted for age, sex, dialysis technique or diabetes mellitus (DM)
showed that the estimated risk of death increased by 4.8% per year increase (HR = 1.048; 95%
CI:  1.04–1.06; p < .001) and was 44% higher in diabetics compared to non-diabetics (HR = 1.44;
95%  CI 1.16–1.76; p < .01). Regarding SV for TT, patients who initiated HD had a shorter
survival than those who initiated PD and transferred to HD (p = .00563).
Conclusion: In our experience, SV in RRT is dependent on age and coexistence of DM.  It would
be  beneﬁcial to reinstate the concept of “comprehensive care”, in which RRT would start with
PD  and later transfer to HD.
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de  técnica.  Experiencia  en  Ourense  1976–2012
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r  e  s  u  m  e  n
Introducción: La supervivencia (SV) comparada en terapia renal sustitutiva (TRS) es dependi-
ente  de la comorbilidad previa al inicio de TRS y no de la técnica dialítica.
Objetivo: Valorar la SV en nuestra población de TRS habida en el periodo 1976–2012 y
asimismo la inﬂuencia por la transferencia de técnica (TTc).
Material y métodos: Cohorte retrospectiva (n = 993 pacientes). Los datos fueron “censurados”
por  trasplante (TX), cambio de técnica, defunción o pérdida para el seguimiento. La SV por
TTc  se realizó en pacientes con más de 12 semanas de permanencia.
Resultados: El riesgo de mortalidad ajustado por edad, sexo, técnica dialítica o diabetes melli-
tus  (DM) mostró que el riesgo estimado de morir aumenta un 4,8% por cada an˜o aumentado
(HR = 1048, IC del 95%, 1,04–1,06, p < 0,001) y este aumenta un 44% en los diabéticos con
respecto a los no diabéticos (HR = 1,44, IC del 95%, 1,16–1,76, p < 0,01). En cuanto a la SV por
TTc, los que inician HD presentan SV menor que los que inician DP y son transferidos a HD
(p  = 0,00563).
Conclusión: En nuestra experiencia, la SV en TRS es dependiente de la edad y la coexistencia
de  DM y sería conveniente retomar el concepto de “cuidados integrales” comenzado la TRS
por  DP y transferir a HD.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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introduction
he survival of uraemic patients on haemodialysis (HD) and
eritoneal dialysis (PD) was compared in several trials over
ecent years, resulting in extended controversy and dissimi-
ar outcomes.1 The reasons accounting for this variability are
omplex, but are basically associated with the use of differ-
nt study designs including non-homogeneous populations,
ifferent types of follow-up, the analysis of incident vs. preva-
ent population, and comorbidities prior to renal replacement
herapy (RRT).1
A number of studies have shown that pre-RRT comor-
idities are the most important factors predicting survival.2,3
herefore, the dialysis modality may not have an independent
ffect on survival; furthermore, studies should be conducted
n the incident patients.4
Since the beginning of the century it was suggested that
oth types of replacement therapy should be considered com-
lementary for the “integral care” of the patient, an approach
hat may improve the survival in RRT.5 This is based on the
dea that RRT should be started with PD and then switched
o HD in case of complications or “lack of efﬁciency” of the
echnique.6,7
Based on these premises, our aim is to assess survival in
oth, HD vs. PD as well as survival resulting from the switch
rom PD to HD in patients from a retrospective cohort of 36-
ear of data collection.
aterials  and  methodshe study includes a retrospective cohort of patients receiv-
ng RRT in our centre between 1976 and 2012. This registry(http://creativecommons.org/licenses/by-nc-nd/4.0/).
includes data on demographics (age, sex, background disease)
change of replacement therapy, transplants, deaths, or change
of address. The original population were 1231 patients; but 223
were excluded because of incomplete data ondemographics;
the ﬁnal study sample was 993 patients.
Statistics: Gaussian variables and non-Gaussian vari-
ables will be presented as mean ± SD and as medians,
respectively. Variables were tested for normality using the
Kolmogorov–Smirnov and Shapiro–Wilk tests. Qualitative
variables will be expressed as frequencies and percentages.
Data were “censored” for transplants, loss or change of
technique, or death.
The survival analysis by dialysis modality was performed
from day 0 and was stratiﬁed by age, with the sample median
as the cut-off value: 65 years of age, sex, and presence or
absence of diabetes mellitus (DM).
Overall survival was estimated in the cohort and in strata
deﬁned by Kaplan–Meier. The relative risks of mortality for
PD vs. HD were assessed by using a Cox regression analysis.
Technique transference was analysed using Kaplan–Meier in
patients who had completed over 12 weeks.
Differences were considered statistically signiﬁcant at a
p < 0.05 in all analyses. Analyses were made by using the R
free software (http://www.r-project.org).
Results
A total of 993 patients were included in the cohort (Table 1).
Elderly patients tended to be started with HD (p = 0.0374) and
the incidence of DM was higher in PD patients (p = 0.000).
The reason to cease the data collection were: a change
in techniques: 91 (9.16%); death: 488 (49.14%); transplant: 271
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Table 1 – Descriptive analysis of the cohort and outcome.
N %
Men 634 63.85
Women 359 36.15
No diabetes mellitus 794 80.77
Diabetes mellitus 189 19.23
HD 685 68.98
PD 308 31.02
HD (n = 685) PD (n = 308) p Value
Age (M ± SD) 60.97 ± 16.23 58.8 ± 16.74 0.0374
Gender (male) 446 (65.11%) 188 (61.04%) 0.2168
Diabetes (yes) 99  (14.6%) 90 (29.51%) 0.0000
Outcome
HD,  n = 685 PD, n = 308
Death 357 52.12% Death 131 42.53%
HD 89 12.99% PD 29 9.42%
Tx 188 27.44% Tx 83 26.95%
Switch to PD 31 4.53% Switch to HD 60 19.48%
LFU 20 2.92% LFU 5 1.62%
 treatHD, haemodialysis; LFU, lost to follow-up; PD, peritoneal dialysis; Tx,
(27.29%); loss to follow-up: 25 (2.52%); and continued PD: 29
(2.92%) and HD: 89 (8.96%).
Survival was lower in patients who started with PD p < 0.05
(Fig. 1a). Median survival time was 1815 days (4.97 years) in
HD and 1255 days (3.44 years) in PD. Cumulative mortality was
52.12% in the HD group and 42.53% in the PD group (p < 0.01).
The survival in consecutive incidents patients in HD
(n = 548) vs. PD (n = 244) in less than 6 months favoured PD
(p = 0.0091) (Fig. 1b). The median survival time in patients start-
ing HD and PD were was 138 days and 173 respectively. The
cumulative mortality in HD patients was 55.95% and 31.67%
in PD patients (p < 0.01).
No differences in survival were found in patients followed
for less than a year (HD, n = 452 and PD, n = 195) (p = 0.1277),
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Fig. 1 – (A) Overall survival in HD vs. PD. (B) Comparison of survi
months.ment.
5 years (HD, n = 149 and PD, n = 29) (p = 0.4287), or 10 years
(p = 0.1057).
When corrected by age, the overall survival was slightly
lower in the PD group. No difference in survival was found
among patients older than 65 years (p = 0.068). Median sur-
vival in HD and PD was 1340 days (3.67 years) and 926 days
(2.53 years), respectively. Cumulative mortality in HD and PD
was 69.04% and 70.23%, respectively (p = 0.8034). No differ-
ences were observed in patients who were 65 years of age or
younger (p = 0.2249), although cumulative mortality was 37.02
in HD and 22.03 in PD (p < 0.001).In relation to gender, survival is higher for incident males
in HD as compared to males starting on PD (p = 0.0064). Median
survival in HD was 1741 days (4.77 years) and 1112 days in PD
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Table 2 – Adjusted mortality risk.
Coefﬁcients SE p Value HR 95% CI for HR
Age (year) 0.0469 0.0040 0.0000 1.0480 (1.04–1.06)
Gender (male) 0.1884 0.1009 0.0620 1.2073 (0.99–1.47)
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Diabetes (yes) 0.3646 0.1114 
3.04 years), while cumulative mortality in HD was 50.9% and
3.62% in men  from the PD group (p = 0.0939). No signiﬁcant
ifferences were observed among women with the two types
f treatment (p = 0.5249); however the cumulative mortality
as 54.39% and 40.83% in HD and PD patients, respectively
p < 0.05).
Overall survival was superior in non-diabetic vs. diabetic
atients (p < 0.001). Median survival in HD was 1910 days (5.23
ears) and 1465 days (4 years) in PD. Cumulative mortality
as 50.09% in HD and 36.74% in PD (p < 0.001). No signiﬁcant
ifferences were observed among incident diabetic patients
ased on dialysis technique (p = 0.3606). Median time on HD
as 1161 days (3.19 years) and 1000 days (2.74 years) in PD.
umulative mortality in the HD and PD groups were 65.66%
nd 56.67% (p = 0.2049) respectively. No differences were found
n non-diabetic patients in HD vs. PD (p = 0.1489).
The mortality risk adjusted for age, gender, technique, and
iabetes (Table 2) shows a 4.8% yearly increase in the esti-
ated risk of death (HR = 1.048, 95% CI, 1.04–1.06, p < 0.001)
nd there is 44% increase in diabetic vs. non-diabetic patients
HR = 1.44, 95% CI, 1.16–1.76, p < 0.01). The analysis of the
mpact of changing technique (PD to HD) was conducted in
54 subjects who  started with HD (who were not transferred)
nd 57 subjects who  had started with PD and later there were
witched to HD. Survival rates of incident patients in HD and
D who  were switched to HD are shown in Fig. 2.
Patients starting on HD have a lower survival rate than
atients who  initiated PD and then switched to HD (p = 0.0563).
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ig. 2 – SV incidents compared between HD and PD
atients transferred HD. SV: actuarial survival; HD:
emodialysis; DP: peritoneal dialysis.0.0418 1.2449 (1.01–1.54)
0.0011 1.4399 (1.16–1.79)
The median survival time of patients starting with HD was
1742 days (4.77 years) and 2566 days (7.02 years) in patients
starting with PD who switched to HD.
Cumulative mortality was 54.59% in HD patients and
50.85% (r = 0.5808, p > 0.05) in PD patients who were switched
to HD.
The analysis of survival in incident patients who were
followed for at least 5 years between HD and PD who  were
switched was not signiﬁcant (p = 0.1767), and neither was the
cumulative mortality (p = 0.7096 > 0.05). However, signiﬁcant
differences were observed in patients followed for 10, 15, and
20 years.
Patients starting with HD had a worse 10-year survival
(p < 0.01) as compared to patients starting with PD who  were
switched to HD. The median survival time in HD was 1621 days
(4.44 years) and 2533 days (6.93 years) in patients starting with
PD who were later switched to HD.
Cumulative mortality in HD patients was 303/506 (53.53%)
and 28/55 (50.91%) (p = 0.7096) in patients who  started with PD
and switched to HD.
The 15-year survival is also worse in HD patients compared
to patients who started with PD and switched to HD (p < 0.05).
The median survival time in patients starting with HD was
1714 days (4.69 years) and 2566 days (7.02 years) in patients
who started with PD and switched to HD. Cumulative mortal-
ity in HD patients was 314/587 (53.49%) and 19/56 (51.79%) in
patients who started with PD and switched to HD (p = 0.8068).
Signiﬁcant differences were still present at 20 years
(p < 0.005). The median survival in patients starting on HD was
1727 days (4.73 years) and 2566 days (7.02 years) in patients
who started with PD and were switched to HD. Cumulative
mortality in the HD group was 320/595 (53.78%) and 30/57
(52.63%) in patients who started with PD and were switched to
HD (p = 0.8679).
Discussion
As a result of the methods used, survival studies on RRT
posed major challenges, complications, and diverse interpre-
tations. As ﬁrst explained in the Ross et al. meta-analysis,3 the
most important factor having an effect on survival is previ-
ous history of comorbidities, while dialysis technique has no
independent and differentiated effect. Under these circum-
stances, the strategy of the statistical analysis should have
a major effect in the ﬁnal outcome. By means of a reﬁned
description, Perez Fontan et al.2 address problems arising in
this type of analysis, essentially including: statistical methods
used, and external and internal validity of studies. In our case,
just as in any other study, the statistical methods used1 were
the univariate analysis of actuarial survival and Kaplan–Meier,
and the Cox multivariate analysis. Even though the latter has
 0 1 5
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certain limitations, including assumed linearity (the effect
of RRT may not be consistent over time) and the consider-
ation of a single terminal event. As far as limitations resulting
from internal validity, cardiovascular and non-cardiovascular
comorbidity of patients is not available, and of course, alloca-
tion of treatment modality is not at random. A comparison of
the baseline characteristics of the sample (Table 1) revealed
that the PD population was younger (p = 0.03749) and the
prevalence of DM was higher (p = 0.0000), and our results are
consistent with other studies,2,4,8,9 where survival is inﬂu-
enced by age and DM,  and this effect is sustained following
the adjustment for comorbidities.2
Survival was higher in PD that HD at 6 months, just as in
other observations,4 but no signiﬁcant differences were seen
at 5 and 10 years, as described.9–11 This outcome is certainly
inﬂuenced by technical improvements both in PD and HD,
early remission in patients in the end-stage chronic renal dis-
ease (ESCRD) consultation and free choice of therapy.1,8,9
The change from PD to HD results in a higher survival rate5
and in our case survival was higher in PD patients who were
transferred to HD as compared to those who  remained in HD,
thereby strengthening the notion of “integrated care” in RRT.
RRT should be started with PD and then switched to HD once
completed or in case of loss of residual renal function.5–7
The study had two basic limitations. The ﬁrst limitation
is that it is a retrospective and that the patient allocation
is not at random, and the second limitation is that no data
were collected on comorbidity, except for age and concurrent
DM,  or variables including dialysis dosing, HD or PD modal-
ity, residual renal function or arteriovenous ﬁstula or catheter.
Nonetheless, an analysis of a database including information
from a 32-year follow-up proves that survival in RRT is higher
when patients start with PD and are later switched to HD, and
that mortality risk is 2.6-fold higher in patients older than
65 years and is increased by 50% in patients with diabetes
mellitus.Conﬂicts  of  interest
The authors declare that there are no conﬂicts of interest.;3 5(6):562–566
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